bristol myer additional info

bristol myer balance sheet

bristol myer income statement

pfizer additional info

pfizer income statement

questions

Pfizer balance sheet

USE THIS INFORMATION ONLY IF NEEDED 2020 2019 Trade receivables 7,882 6,888 Less charge-backs & cash discounts 645 391 Less allowance for expected credit loss 18 21 2018 4,914 245 33 2017 4,599 209 43 187 6,336 3,157 Land Buildings Machinery, equipment & fixtures Construction in progress Gross property, plant & equipment Less accumulated depreciation 189 5,732 3,063 487 9,471 3,585 104 5,231 2,962 548 8,845 3,818 100 4,848 3,059 980 8,987 3,986 527 10,207 3,955 Tax rate 35% 35% 35% 35% Net cash flows from operating activities 14,052 8,067 5,940 5,275 Bristol Myers Squibb Co. (NYS: BMY) Report Date Cash & cash equivalents Marketable debt securities Receivables, net Inventories, net Prepaid expenses & other current assets Total current assets Property, plant & equipment, net Goodwill Other intangible assets Deferred income taxes Marketable debt securities Other non-current assets Total assets 2020 14,546 1,285 8.501 2.074 3.786 30,192 5,886 20.547 53,243 1.161 433 7,019 118,481 2019 12,346 3,047 7,685 4.293 1,983 29,354 6,252 22,488 63.969 510 767 6,604 129,944 2018 6.911 1.973 5.965 1,195 1.116 17,160 5,027 6,538 1.091 1.371 1.775 2.024 34,986 2017 5,421 1,391 6,300 1,166 576 14,854 5,001 6,863 1,210 1.610 2,480 1,533 33,551 2.340 2.713 14 027 19,080 5,407 48,336 7.776 80,599 3,346 2.445 12,513 18,304 6,454 43,387 10.101 78,246 1.703 1,892 7,059 10,654 4,559 5,646 987 2.248 6,328 9,563 5.166 6,975 20,859 21,704 Liabilities Short-term debt obligations Accounts payable Other current liabilities Total current liabilities Deferred income taxes Long-term debt Other non-current liabilities Total liabilities Stockholders' Equity Common stock Capital in excess of par value of stock Accumulated other comprehensive income (loss) Retained earnings Less cost of treasury stock Non-controlling interest Total equity 292 44,325 (1.839) 21,281 26,237 60 37.882 292 43,709 (1,520) 34,474 25,357 100 51,698 221 2.081 (2,762) 34,065 19,574 96 14,127 221 1,898 (2.289) 31,160 19,249 106 11,847 Accounts receivable, gross Less allowance for doubtful accounts USE THIS INFORMATION ONLY IF NEEDED 2020 2019 8,438,000 9,251,000 508,000 527.000 2018 8,566,000 541,000 2017 8,805,000 584,000 Land 444,000 Buildings 9,022,000 Machinery & equipment 11.153,000 Furniture, fixtures & other property, 4,541,000 Construction in progress 3,552.000 Property, plant & equipment, at cost 28,712,000 Less: accumulated depreciation 14,812,000 Tax rate 35% 516,000 10.068,000 12.281.000 4.930,000 2.960.000 30,755.000 16,788,000 500,000 9.920,000 11,871,000 4,693,000 2.992.000 29,976,000 16,591,000 540,000 10.254.000 11,902,000 4,661,000 2,680,000 30,037,000 16,172,000 35% 35% 35% Cash from operations 14,403,000 12,588,000 15,827,000 16,470,000 USE 2017 INFORMATION ONLY FOR CALCULATION OF RATIOS. Pfizer Inc (NYS: PFE) Report Date 2020 2019 Cash & cash equivalents 1.784 000 1,305,000 Short-term investments 10,437 000 8.525,000 Trade accounts receivable 7.930 000 8,724 000 Inventories 8,047.000 8 284 000 Current tax assets 3,264,000 3.344,000 Other current assets 3,438,000 2.600.000 Assets held for sale 167,000 21,000 Total current assets 35,067.000 32,803,000 Equity-method investments 16,856,000 17 133 000 Long-term investments 3,406 000 3.014 000 Property, plant & equipment 13.900.000 13,967.000 Identifiable intangible assets 28.471.000 35.370,000 Goodwill 49,577 000 58 653,000 Noncurrent deferred tax assets & other noncurrent tax assets 2.383.000 2,099.000 Other noncurrent assets 4,569.000 4 450,000 Total assets 154,229,000 167,489,000 2018 1,139,000 17,694,000 8.025 000 7 508,000 3,374,000 2.461,000 9.725.000 49,926,000 2017 1,342,000 18,650,000 8.221 000 7,577,000 3.050.000 2.289.000 12,000 41,141,000 2.767 000 13,385.000 35.210,000 53,411,000 1.924 000 2,799,000 159.422,000 7,015.000 13,865,000 48 742.000 55 952.000 1.855.000 3.227.000 171.797,000 Liabilities Short-term borrowings, including current portion of long-term debt Trade accounts payable Dividends payable Income taxes payable Accrued compensation & related items Other current habilities Total current liabilities Long term debt Pension benefit obligations Postretirement benefit obligations Noncurrent deferred tax liabilities Other taxes payable Other noncurrent liabilities Total liabilities 2.703.000 4,309,000 2.162.000 1.049,000 3,057,000 12,640,000 25,920,000 37.133.000 4.766,000 645.000 4,063,000 11.560 000 6,669,000 90,756,000 16.195.000 4 220.000 2.104.000 980 000 2.722.000 11,083 000 37,304,000 35.955.000 5.638,000 1.124.000 5,578,000 12.126,000 6,317 000 104,042,000 8,831,000 4.674,000 2 047.000 1,265,000 2.398000 12 643 000 31,858,000 32 909.000 5.272 000 1,338,000 3.700.000 14 737 000 5,850,000 95,664,000 9.953,000 4.656,000 2029.000 477 000 2,197 000 11.115,000 30,427,000 33,538.000 5.926.000 1,504.000 3.900.000 18,697 000 6,149,000 100,141,000 Stockholders' Equity Preferred stock Common stock Additional paid-in capital Treasury stock Retained earnings (accumulated deficit) Accumulated other comprehensive income foss) Equity attributable to noncontrolling interests Total equity (deficit) 470.000 88,674,000 110,988,000 96,770,000 (11,688,000) 235,000 63,473,000 17,000 468,000 87 428,000 110 801,000 97 670 000 (11 640,000) 305,000 63,447,000 19.000 467.000 86,253,000 101,510.000 89,554,000 (11.275.000) 350,000 63.758,000 21.000 464.000 84 278 000 89.425.000 85,291,000 (9.321.000) 348.000 71,656,000 2020 2018 53,647.000 11,248,000 42,399,000 14 455,000 8,006,000 4.893,000 1,044,000 Pfizer Inc (NYS: PFE) Report Date Revenues Cost of sales Gross Profit Selling informational & administrative expenses Research & development expenses Amortization of intangible assets Restructuring charges & certain acquisition-related costs Gain (loss) on completion of Consumer Healthcare JV transaction Interest income Interest expense Royalty-related income other expenses Income (loss) from continuing operations before provision for taxes on income Provision (benefit) for taxes on income Income (loss) from continuing operations after provision for taxes on income Income (loss) from discontinued operations.net of tax Net income before allocation to noncontrolling interests Less: net income attributable to noncontrolling interests Net income attributable to Pfizer Inc. 41,908,000 8,692,000 33,216,000 11.615.000 9,405,000 3,436.000 600,000 6.000 73.000 1.449.000 770.000 63,000 7.497,000 476,000 7,021,000 2.631,000 9,652,000 (36.000) 9,616,000 2019 51,750,000 10,219.000 41,531,000 14,350,000 8,650,000 4,610,000 747,000 8,086,000 226,000 1,574,000 648.000 2,878,000 17,682,000 1,384,000 16,298,000 4.000 16,302,000 (29.000) 16,273,000 333,000 1,316,000 495.000 1,628,000 11,885,000 706,000 11,179,000 9,000 11,188,000 (35 000) 11,153,000 (3) Prepare ratio analyses (for 2020, 2019, and 2018) for both companies. You should include the following ratios in your computations: Profitability ratios o Gross Profit margin o Profit margin o Return on assets o Return on equity Productivity o Inventory Turnover o Accounts Receivable Turnover OPPE Turnover o Asset Turnover Solvency o Debt-to-equity o Times interest earned o Return on Financial leverage Liquidity o Current Ratio o Quick Ratio o Operating cash flow to current liabilities o Working capital USE 2017 INFORMATION ONLY FOR CALCULATION OF RATIOS. Pfizer Inc (NYS: PFE) Report Date 2020 2019 Cash & cash equivalents 1.784 000 1,305,000 Short-term investments 10,437 000 8.525,000 Trade accounts receivable 7.930 000 8,724 000 Inventories 8,047.000 8 284 000 Current tax assets 3,264,000 3.344,000 Other current assets 3,438,000 2.600.000 Assets held for sale 167,000 21,000 Total current assets 35,067.000 32,803,000 Equity-method investments 16,856,000 17 133 000 Long-term investments 3,406 000 3.014 000 Property, plant & equipment 13.900.000 13,967.000 Identifiable intangible assets 28.471.000 35.370,000 Goodwill 49,577 000 58 653,000 Noncurrent deferred tax assets & other noncurrent tax assets 2.383.000 2,099.000 Other noncurrent assets 4,569.000 4 450,000 Total assets 154,229,000 167,489,000 2018 1,139,000 17,694,000 8.025 000 7 508,000 3,374,000 2.461,000 9.725.000 49,926,000 2017 1,342,000 18,650,000 8.221 000 7,577,000 3.050.000 2.289.000 12,000 41,141,000 2.767 000 13,385.000 35.210,000 53,411,000 1.924 000 2,799,000 159.422,000 7,015.000 13,865,000 48 742.000 55 952.000 1.855.000 3.227.000 171.797,000 Liabilities Short-term borrowings, including current portion of long-term debt Trade accounts payable Dividends payable Income taxes payable Accrued compensation & related items Other current habilities Total current liabilities Long term debt Pension benefit obligations Postretirement benefit obligations Noncurrent deferred tax liabilities Other taxes payable Other noncurrent liabilities Total liabilities 2.703.000 4,309,000 2.162.000 1.049,000 3,057,000 12,640,000 25,920,000 37.133.000 4.766,000 645.000 4,063,000 11.560 000 6,669,000 90,756,000 16.195.000 4 220.000 2.104.000 980 000 2.722.000 11,083 000 37,304,000 35.955.000 5.638,000 1.124.000 5,578,000 12.126,000 6,317 000 104,042,000 8,831,000 4.674,000 2 047.000 1,265,000 2.398000 12 643 000 31,858,000 32 909.000 5.272 000 1,338,000 3.700.000 14 737 000 5,850,000 95,664,000 9.953,000 4.656,000 2029.000 477 000 2,197 000 11.115,000 30,427,000 33,538.000 5.926.000 1,504.000 3.900.000 18,697 000 6,149,000 100,141,000 Stockholders' Equity Preferred stock Common stock Additional paid-in capital Treasury stock Retained earnings (accumulated deficit) Accumulated other comprehensive income foss) Equity attributable to noncontrolling interests Total equity (deficit) 470.000 88,674,000 110,988,000 96,770,000 (11,688,000) 235,000 63,473,000 17,000 468,000 87 428,000 110 801,000 97 670 000 (11 640,000) 305,000 63,447,000 19.000 467.000 86,253,000 101,510.000 89,554,000 (11.275.000) 350,000 63.758,000 21.000 464.000 84 278 000 89.425.000 85,291,000 (9.321.000) 348.000 71,656,000